Nevirapine toxicity

B. O. Taiwo*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

32 Scopus citations


The number of HIV-infected patients who are newly exposed to nevirapine is increasing worldwide. To minimize toxicity, clinicians must adhere to dosing guidelines, avoid prescribing the drug in patients with known increased risk of toxicity, and promptly recognize toxicities, which are mainly cutaneous and hepatic. These toxicities are more common with nevirapine than with efavirenz. Women with CD4 counts >250 cells/mm3 have particularly increased susceptibility to nevirapine toxicity. Improved understanding of the pathogenesis of nevirapine toxicity, and its relationship with pharmacokinetic parameters, genetic factors and cellular immune kinetics will enhance our ability to reduce the risk to the HIV-infected individual.

Original languageEnglish (US)
Pages (from-to)364-370
Number of pages7
JournalInternational Journal of STD and AIDS
Issue number6
StatePublished - Jun 2006


  • Hepatitis
  • Nevirapine
  • Rash
  • Toxicity

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Pharmacology (medical)
  • Infectious Diseases
  • Dermatology


Dive into the research topics of 'Nevirapine toxicity'. Together they form a unique fingerprint.

Cite this